Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving short-term infliximab therapy

Cytokine

Volumn 30, Issue 2, 2005, Pages 72-77

  Popa, Calin ^a   Netea, Mihai G ^a   Barrera, Pilar ^a   Radstake, Timothy R D S ^a   Van Riel, Piet L ^a   Kullberg, Bart Jan ^a   Van Der Meer, Jos W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti tumor necrosis factor; Cytokine; Infection; Rheumatoid arthritis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ASPERGILLUS FUMIGATUS; BLOOD CULTURE; CANDIDA ALBICANS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; INFECTION RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; STIMULATION;

EID: 15944399432     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2004.12.012     Document Type: Article

References (26)

1. M. Feldmann, and R.N. Maini The role of cytokines in the pathogenesis of rheumatoid arthritis Rheumatology (Oxford) Suppl 2 1999 3 7
2. R. Maini, E.W. St Clair, F. Breedveld, D. Furst, J. Kalden, and M. Weisman Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group Lancet 354 1999 1932 1939
3. P. Barrera, A. van der Maas, A.E. van Ede, B.A. Kiemeney, R.F. Laan, and L.B. van de Putte Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis Rheumatology (Oxford) 41 2002 430 439
4. M.C. Hochberg, J.K. Tracy, M. Hawkins-Holt, and R.H. Flores Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis Ann Rheum Dis Suppl 2 2003 II13 II16
5. M.C. Genovese, J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, and M.H. Schiff Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes Arthritis Rheum 46 2002 1443 1450
6. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent N Engl J Med 345 2001 1098 1104
7. C.A. Dinarello Anti-cytokine therapeutics and infections Vaccine Suppl 2 2003 S24 S34
8. R.S. Wallis, M.S. Broder, J.Y. Wong, M.E. Hanson, and D.O. Beenhouwer Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 38 2004 1261 1265
9. A. Warris, A. Bjorneklett, and P. Gaustad Invasive pulmonary aspergillosis associated with infliximab therapy N Engl J Med 344 2001 1099 1100
10. N.R. Slifman, S.K. Gershon, J.H. Lee, E.T. Edwards, and M.M. Braun Listeria monocytogenes infection as a complication of treatment with tumour necrosis factor alpha-neutralizing agents Arthritis Rheum 48 2003 319 324
11. M.G. Netea, T. Radstake, L.A. Joosten, J.W. van der Meer, P. Barrera, and B.J. Kullberg Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression Arthritis Rheum 48 2003 1853 1857
12. R. van Crevel, T.H. Ottenhoff, and J.W. van der Meer Innate immunity to Mycobacterium tuberculosis Clin Microbiol Rev 15 2002 294 309
13. M.A. Gardam, E.C. Keystone, R. Menzies, S. Manners, E. Skamene, and R. Long Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management Lancet Infect Dis 3 2003 148 155
14. H. Kaneko, H. Yamada, S. Mizuno, T. Udagawa, Y. Kazumi, and K. Sekikawa Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice Lab Invest 79 1999 379 386
15. G. Senaldi, S. Yin, C.L. Shaklee, P.F. Piguet, T.W. Mak, and T.R. Ulich Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI J Immunol 157 1996 5022 5026
16. N. Ismail, J.P. Olano, H.M. Feng, and D.H. Walker Current status of immune mechanisms of killing of intracellular microorganisms FEMS Microbiol Lett 207 2002 111 120
17. A.M. Cooper, D.K. Dalton, T.A. Stewart, J.P. Griffin, D.G. Russell, and I.M. Orme Disseminated tuberculosis in interferon gamma gene-disrupted mice J Exp Med 178 1993 2243 2247
18. M.J. Newport, C.M. Huxley, S. Huston, C.M. Hawrylowicz, B.A. Oostra, and R. Williamson A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection N Engl J Med 335 1996 1941 1949
19. R. Jacobs, C.R. Pawlak, E. Mikeska, D. Meyer-Olson, M. Martin, and C.J. Heijnen Systemic lupus erythematosus and rheumatoid arthritis patients differ from healthy controls in their cytokine pattern after stress exposure Rheumatology (Oxford) 40 2001 868 875
20. A. Reuter, J. Bernier, Y. Vrindts-Gevaert, R. Meuleman-Gathy, M. Malaise, and W. Fiers Production of interferon gamma by peripheral blood mononuclear cells from normal subjects and from patients with rheumatoid arthritis Clin Exp Rheumatol 6 1988 347 354
21. P. Loubet-Lescoulie, A. Constantin, B. Mazieres, J. Tkaczuk, C. de Preval, and A. Cantagrel Decreased peripheral blood T cell cytokine gene expression in rheumatoid arthritis Scand J Rheumatol 28 1999 244 251
22. P. Miossec, and W. van den Berg Th1/Th2 cytokine balance in arthritis Arthritis Rheum 40 1997 2105 2115
23. H. Schulze-Koops, and J.R. Kalden The balance of Th1/Th2 cytokines in rheumatoid arthritis Best Pract Res Clin Rheumatol 15 2001 677 691
24. A.J. Schuerwegh, J.F. Van Offel, W.J. Stevens, C.H. Bridts, and L.S. De Clerck Influence of therapy with chimeric monoclonal tumour necrosis factor-alpha antibodies on intracellular cytokine profiles of T lymphocytes and monocytes in rheumatoid arthritis patients Rheumatology (Oxford) 42 2003 541 548
25. Safety update on TNF-α antagonists: infliximab and etanercept. Food and Drug Administration, Center for Biologics Evaluation and Research. Arthritis Advisory Committee Meeting. http://www.fda.gov/ohrms/dockets/ac/01/ brieffing/3779b2.htm.
26. R. van Crevel, J. van der Ven-Jongekrijg, M.G. Netea, W. de Lange, B.J. Kullberg, and J.W. van der Meer Disease-specific ex vivo stimulation of whole blood for cytokine production: applications in the study of tuberculosis J Immunol Methods 222 1999 145 153